Market Overview

UPDATE: Bank of America Upgrades Myriad Genetics to Buy on Diversification Strategy

Share:
Related MYGN
Big Short Interest On These 5 Biotech Stocks
Barclays Initiates Coverage On Life Science Tools & Diagnostics, Names Thermo Fisher As 'Top Pick'

Bank of America raised its rating on Myriad Genetics (NASDAQ: MYGN) from Neutral to Buy and increased its price objective from $30 to $32.

Bank of America commented, "We upgrade MYGN shares to Buy from Neutral, as we are more positive on the company's efforts to diversify the business and expand its addressable markets, particularly as the company's flagship product, BRACAnalysis, matures. We think MYGN's strategy to increase its penetration in certain cancer indications while expanding overseas is viable, and are more optimistic on the ability to protect the BRACAnalysis franchise. We are also incrementally more positive on Prolaris and the pipeline, as well as the company's efforts in companion diagnostics."

Myriad Genetics closed at $25.37 on Tuesday.

Latest Ratings for MYGN

DateFirmActionFromTo
Nov 2014Morgan StanleyInitiates Coverage onUnderperform
Aug 2014Credit SuisseMaintainsNeutral
Jun 2014MacquarieMaintainsNeutral

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (MYGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional